Cognition's CT1812 well tolerated in Phase Ib/IIa trial for AD

Cognition Therapeutics Inc. (Pittsburgh, Pa.) reported data from the Phase Ib/IIa COG0102 trial in 19 patients with mild to moderate Alzheimer’s disease showing that all 3 doses of CT1812 were well tolerated with no serious adverse events reported. The company said cognitive outcomes after 28 days were “similar” across the CT1812 and placebo arms.

Cognition also said that CT1812 led to a “marked reduction” in synaptotagmin-1 levels in cerebrospinal fluid (CSF) vs. placebo, and significantly reduced CSF neurogranin (NRGN) levels vs. placebo. Data were presented at the Clinical Trials on Alzheimer's Disease meeting in Boston...